2025-04-24 - Analysis Report
## Johnson & Johnson (JNJ) Stock Report

**0. Executive Summary:**

Johnson & Johnson (JNJ), a multinational healthcare corporation, shows a cumulative return significantly lower than the S&P 500 (VOO) over the analyzed period.  While exhibiting relatively stable profitability and consistent revenue, recent performance lags behind the market benchmark.  Further analysis is needed to determine the long-term investment viability.

**1. Performance Comparison & Alpha/Beta Analysis:**

JNJ's cumulative return is 38.07%, while the S&P 500 (VOO) achieved 78.93%. This represents a significant lag of -40.9%, placing JNJ at the 36.8th percentile of its historical relative performance against the S&P 500 based on provided min/max range.

The provided alpha/beta analysis reveals inconsistent performance relative to the market (beta) and varying levels of alpha (outperformance) across different periods.  Noteworthy is the negative CAGR (-17% and -31%) in the most recent two-year periods (2021-2023 and 2022-2024), significantly impacting overall returns.  The market cap remains relatively stable, fluctuating between approximately $260B and $400B during the analyzed periods.

**2. Recent Price Movement:**

* **Closing Price:** $155.38
* **5-Day Moving Average:** $156.29
* **20-Day Moving Average:** $155.87
* **60-Day Moving Average:** $158.38

The price is currently below all three moving averages, suggesting a bearish short-term trend.  The recent close is lower than the previous close (-$1.5), indicating a slight downward pressure.

**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4174 (Medium Risk)
* **RSI:** 50.03 (Neutral)
* **PPO:** 0.30 (Slightly bullish, but close to neutral)
* **20-Day Relative Strength Change:** -1.6 (Short-term downward trend)
* **Expected Return:** -44.9% (relative to S&P 500 over the long term)

The technical indicators suggest a relatively neutral market sentiment. The negative expected return indicates that JNJ's predicted long-term (2+ years) performance is significantly lower than that of the S&P 500.  The recent price drop reflects current market concerns.

**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
|------------|-------|---------------|
| 2025-04-23 | 4.57  | $21.89B       |
| 2024-10-23 | 1.12  | $22.47B       |
| 2024-07-25 | 1.95  | $22.45B       |
| 2024-05-01 | 1.35  | $21.38B       |
| 2025-04-23 | 1.35  | $21.38B       |


There appears to be a duplicate entry for 2025-04-23.  EPS and revenue show variability, lacking a consistent upward trend.  Further investigation is needed to understand the reasons behind this variation.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue     | Profit Margin |
|-------------|-------------|---------------|
| 2024-12-31 | $22.52B     | 68.35%        |
| 2024-09-30 | $22.47B     | 69.01%        |
| 2024-06-30 | $22.45B     | 69.40%        |
| 2024-03-31 | $21.38B     | 69.55%        |
| 2023-12-31 | $21.39B     | 68.23%        |


Revenue remains relatively stable, while profit margins are consistently high, hovering around 70%.

**Capital and Profitability:**

| Quarter     | Equity      | ROE     |
|-------------|-------------|---------|
| 2024-12-31 | $71.49B     | 4.80%  |
| 2024-09-30 | $70.16B     | 3.84%  |
| 2024-06-30 | $71.54B     | 6.55%  |
| 2024-03-31 | $70.02B     | 4.65%  |
| 2023-12-31 | $68.77B     | 5.89%  |

Equity fluctuates slightly, and ROE shows some variability.


**6. Overall Analysis:**

JNJ demonstrates consistent revenue and high profit margins, indicating financial stability. However, its recent underperformance compared to the S&P 500, negative CAGR in recent years and a negative long-term expected return raise concerns.  The neutral technical indicators don't provide a clear buy/sell signal.  Further investigation into the reasons for the recent underperformance (e.g., sector-specific headwinds, competitive pressures, or changes in investor sentiment) is crucial before making any investment decisions.  The data suggests a cautious approach is warranted.  Despite its financial stability, its current market underperformance warrants a deeper analysis before considering a long-term investment.
